Clinical Profile of Cyclooxygenase-2 Inhibitors in Treating Non-Small Cell Lung Cancer: A Meta-Analysis of Nine Randomized Clinical Trials

BACKGROUND: Evidence on the benefits of combining cyclooxygenase-2 inhibitor (COX-2) in treating non-small cell lung cancer (NSCLC) is still controversial. We investigated the efficacy and safety profile of cyclooxygenase-2 inhibitors in treating NSCLC. METHODS: The first meta-analysis of eligible s...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yuan Yuan, Hu, Zhi Gang, Zeng, Fan Jun, Han, Jiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805232/
https://www.ncbi.nlm.nih.gov/pubmed/27007231
http://dx.doi.org/10.1371/journal.pone.0151939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805232/
https://www.ncbi.nlm.nih.gov/pubmed/27007231
http://dx.doi.org/10.1371/journal.pone.0151939

Ejemplares similares